Početna › Limfom › Texas › Houston
Kliničke studije za Limfom u gradu Houston, TX
34 studija za Limfom traži sudionike na lokacijama u gradu Houston i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
U tijeku regrutacijaFaza 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
U tijeku regrutacijaOpažajna studija
- Texas Children's Hospital, Houston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
U tijeku regrutacijaFaza 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
U tijeku regrutacijaFaza 2
- MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
U tijeku regrutacijaFaza 1/2
- Baylor College of Medicine, Houston
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
U tijeku regrutacijaFaza 1
- University of Texas - MD Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
U tijeku regrutacijaFaza 1/2
- Research Site, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
U tijeku regrutacijaFaza 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
U tijeku regrutacijaFaza 3
- Research Site, Houston
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
U tijeku regrutacijaFaza 1
- Baylor College of Medicine, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
U tijeku regrutacijaFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
U tijeku regrutacijaFaza 1/2
- MD Anderson, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
U tijeku regrutacijaFaza 1/2
- MD Anderson Cancer Center, Houston
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
U tijeku regrutacijaFaza 2
- MD Anderson Cancer Center, Houston
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
U tijeku regrutacijaFaza 1
- UT MD Anderson, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
U tijeku regrutacijaFaza 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
U tijeku regrutacijaFaza 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
U tijeku regrutacijaFaza 1
- The University of Texas M D Anderson Cancer Center, Houston
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
U tijeku regrutacijaFaza 2
- MD Anderson Cancer Center, Houston
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
U tijeku regrutacijaFaza 2
- MD Anderson Cancer Center, Houston
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
U tijeku regrutacijaFaza 2
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
U tijeku regrutacijaFaza 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
U tijeku regrutacijaFaza 1
- MD Anderson, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
U tijeku regrutacijaFaza 1
- MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
U tijeku regrutacijaFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
U tijeku regrutacijaFaza 1/2
- Dren Investigational Site, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
U tijeku regrutacijaOpažajna studija
- M D Anderson Cancer Center, Houston
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
U tijeku regrutacija
- MD Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
U tijeku regrutacijaOpažajna studija
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
U tijeku regrutacijaFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
U tijeku regrutacijaFaza 1
- MD Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
U tijeku regrutacijaFaza 2
- MD Anderson, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
U tijeku regrutacijaFaza 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
U tijeku regrutacijaFaza 1
- The University of Texas MD Anderson Cancer Center, Houston
Studije za Limfom u drugim gradovima
- Boston, MA33 studija
- New York City, NY33 studija
- Washington, DC23 studija
- Baldwin Park, CA21 studija
- Chicago, IL20 studija
- Durham, NC17 studija
- St. Louis, MO15 studija
- Philadelphia, PA15 studija
- Cleveland, OH14 studija
- Edison, NJ12 studija
- Atlanta, GA12 studija
- Seattle, WA12 studija
Ostale studije u gradu Houston
- Nemikrocelularni karcinom pluća145 studija
- Rak dojke126 studija
- Rak (sve vrste)121 studija
- Metastatski karcinom104 studija
- Kolorektalni rak102 studija
- Rak jajnika89 studija
- Akutna mijeloična leukemija85 studija
- Rak pluća78 studija
- Rak prostate76 studija
- Rak endometrija68 studija
- Rak gušterače61 studija
- Melanom59 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.